Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radiocontrast-induced nephropathy: Correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol

Investigative Radiology

Volumn 40, Issue 9, 2005, Pages 598-603

  Sherwin, Paul F ^a   Cambron, Richard ^a   Johnson, Judith A ^a   Pierro, Joseph A ^a  

^a GE HEALTHCARE   (United States)

Author keywords

Contrast media; Iodixanol; Kidney failure; Risk factors

Indexed keywords

CONTRAST MEDIUM; EDETATE CHROMIUM CR 51; IODIXANOL;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG INDUCED DISEASE; HUMAN; HUMAN EXPERIMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 23944456404     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000174476.62724.82     Document Type: Article

References (51)

1. Rudnick MR, Berns JS, Cohen RM, et al. Contrast media-associated nephrotoxicity. Semin Nephrol. 1997;17:15-26.
2. Haller C, Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol. 2004;39:149-154.
3. Andrew E, Berg KJ, Nephrotoxic effects of x-ray contrast media. J Toxicol Clin Toxicol. 2004;42:325-332.
4. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
5. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
6. Morcos SK. Prevention of contrast media nephrotoxicity-the story so far. Clin Radiol. 2004;59:381-389.
7. Maeder M, Klein M, Fehr T, et al. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44:1763-1771.
8. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004;44:327-337.
9. Cavusoglu E, Chhabra S, Marmur JD, et al. The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol. 2004;52:419-432.
10. Gomes AS, Baker JD, Martin-Paredero V, et al. Acute renal dysfunction after major arteriography. AJR Am J Roentgenol. 1985;145: 1249-1253.
11. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90:1068-1073.
12. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
13. Talierco CP, Vlietstra RE, Fisher LD, et al. Risks for renal dysfunction with cardiac angiography. Ann Intern Med. 1986;104:501-504.
14. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990;150:1237-1242.
15. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9: 1602-1613.
16. Albert SG, Shapiro MJ, Brown WW, et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol. 1994;29:618-623.
17. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298-303.
18. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254-261.
19. Lang EK, Foreman J, Schlegel JU, et al. The incidence of contrast medium induced acute tubular necrosis following arteriography. Radiology. 1981;138:203-206.
20. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-620.
21. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol. 1991;157:49-58.
22. D'Elia JA, Gleason RE, Alday M, et al. Nephrotoxicity from angiographic contrast material. A prospective study. Am J Med. 1982;72:719-725.
23. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
24. Nikonoff T, Skau T, Berglund J, et al. Effects of femoral arteriography and low osmolar contrast agents on renal function. Acta Radiol. 1993; 34:88-91.
25. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983;141:1027-1033.
26. Rasmussen HH, Ibels LS. Acute renal failure. Multivariate analysis of causes and risk factors. Am J Med. 1982;73:211-218.
27. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int. 1992;41:1274-1279.
28. US Food and Drug Administration. Toxicokinetics: the assessment of systemic exposure in toxicity studies. Guideline. 1995. Available at: http://www.fda.gov/cder/guidance/ichs3a.pdf. Accessed January 20, 2005.
29. Chen ML, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet. 2001;40: 565-572.
30. Bourin M, Jolliet P, Ballereau F. An overview of the clinical pharmacokinetics of x-ray contrast media. Clin Pharmacokinet. 1997;32:180-193.
31. Dean PB, Kivisaari L, Kormano M. The diagnostic potential of contrast enhancement pharmacokinetics. Invest Radiol. 1978;13:533-540.
32. Dean PB, Kivisaari L, Kormano M. Contrast enhancement pharmacokinetics of six ionic and nonionic contrast media. Invest Radiol. 1983; 18:368-374.
33. Frennby B, Sterner G. Contrast media as markers of GFR. Eur Radiol. 2002;12:475-484.
34. Corradi A, Menta R, Cambi V, et al. Pharmacokinetics of iopamidol in adults with renal failure. Arzneimittelforschung. 1990;40:830-832.
35. Lorusso V, Taroni P, Alvino S, et al. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis. Invest Radiol. 2001;36: 309-316.
36. Nossen JO, Jakobsen JA, Kjaersgaard P, et al. Elimination of the non-ionic x-ray contrast media iodixanol and iohexol in patients with severely impaired renal function. Scand J Clin Lab Invest. 1995;55:341-350.
37. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42: 493-500.
38. el-Sayed YM. Correlation between nephrotoxicity and pharmacokinetic parameters of gentamicin. J Clin Pharmacol Ther. 1994;19: 267-271.
39. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999;19:1252-1260.
40. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-1555.
41. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520-528.
42. Colby C, Koziol S, McAfee SL, et al. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant. 2002;29:467-472.
43. Lewis LD, Burton LC, Harper PG, et al. Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin. Eur J Cancer. 1992;28A:1976-1981.
44. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;17:1748-1756.
45. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649-652.
46. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
47. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;15:90:1068-1073.
48. Svaland MG, Haider T, Langseth-Manrique K, et al. Human pharmacokinetics of iodixanol. Invest Radiol. 1992;27:130-133.
49. Brochner-Mortensen J, Rodbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest. 1976;36:35-43.
50. Dietrich S, Fodor J, Malott JC, et al. Monitoring the iodine dose. Radiol Manage. 1984;6:16-18.
51. Boijsen M, Granerus G, Jacobsson L, et al. Glomerular filtration rate estimated after multiple injections of contrast medium during angiography. Acta Radiol. 1988;29:669-674.